Filip Poelaert

#SESAUA26 State of the Art Lecture @sanojpunnen PCa Screening Guidelines: ♦️Start: 45-50 yrs ♦️Screen q2-4 yrs if PSA < 1 ♦️Screen q1-2 yrs if PSA >1 ♦️Intervene: PSA 3-4 ♦️Stop: 70-75 yrs or life expectancy < 10 yrs @urotoday

Impact of 1g Tranexamic Acid on Outcomes in EEP Patients 🩸 Reduced bleeding complications with TXA (OR 0.17) ⏲ Shortest hemostasis time with TXA (p < 0.001) 📈 Higher bleeding risk on blood thinners (OR 2.93) @DocGauhar @trwherrmann @ytanidir @drabhaymahajan @doc_sarvajit @endouro @D_Castellani @steffiyuen

🌍 Global patient reported outcomes (PROs) after localized #ProstateCancer treatment 👇New data from 27,499 patients across 16 countries (TrueNTH Registry) Big predictors 🏁 Baseline function matters most 🏥 Treatment modality drives domain-specific tradeoffs 12-mo outcomes 🔴 RP → ↓ urinary continence & sexual function 📡 EBRT + ADT → ↓ bowel & hormonal function 🟢 AS → smallest functional declines Reality check ⚠️Global models explain only ~14–32% of variance 🌐 Major regional heterogeneity → one-size models fall short 🎯 Takeaway Personalized counseling needs baseline function + local context, not just treatment labels 🔗shorturl.at/bjBcf @UCLAHealthJCCC @UclaUrology @CS_Urology @CSCancerCenter @UrologyTimes @PCFnews @renalandurology @urotoday

🚨 New ESMO guideline on localized & locoregional prostate cancer! annalsofoncology.org/article/S0923-… 💥 Clear algorithms for diagnosis, risk stratification & treatment 🎯 Active surveillance where appropriate & escalation when needed 🤝 Multidisciplinary (evidence-based) globally aligned Good oncology isn’t about doing more…it’s about doing it right!! Congrats to @AttardLab @Ecastromarcos @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @MarkARubin1 @ChrisSweens1 @Tilki_De @ZilliThomas @alison_tree and all the team! 👏🏼 @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM

PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance open.substack.com/pub/beyondthea…

🤖🆚🗡️ Robotic vs open partial nephrectomy for complex kidney tumors 👏Tested in an RCT (OpeRa trial) @Annals_Oncology 🔑🔑 Takeaways: ⚖️ 30-day complications: no significant difference (RAPN 37% vs OPN 46%) ⏱️ RAPN = longer OR + warm ischemia time 🏥 RAPN = shorter hospital stay 💊 Less opioids, less pain 😊 Better QoL through POD30 ⭐️ RAPN not clearly safer, but easier on patients in the short term — even for intermediate/high-complexity tumors 🔗shorturl.at/dUbgk @urotoday @renalandurology @UrologyTimes

Hoeveel verdienen ASO’s na indexering? - despecialist.eu/nl/nieuws/bero… @TweetsVaso @bvastweets @ASGB_KARTEL

Transparantiecodes en pseudocodes: wat u werkelijk codeert - despecialist.eu/nl/nieuws/bero…

✨ New evidence in high-risk prostate cancer staging! ✨ A large multi-institutional study from @Uroweb Young Academic Prostate Cancer group shows that patients staged with PSMA-PET before surgery experience better short-term oncologic outcomes than those staged with conventional imaging. 📌 Key highlights: ✔️ Lower PSA persistence rates ✔️ Higher biochemical recurrence-free survival at 36 months (90.9% vs 82.2%) ✔️ PSMA-PET was an independent predictor of improved outcomes ➡️ These results underscore the importance of accurate preoperative staging to guide treatment and patient selection. 🔍 Full citation: sciencedirect.com/science/articl… #ProstateCancer #Urology @EAU_YAUProstate @dr_rajwa @GGandaglia @NICOLETTIRosse1

Het is duidelijk uit de analyses van de laatste dagen, alsook uit de discussies in de plenaire en de commissie dat de Kaderwet geen afgeronde zaak is. Juridisch zijn er enkele hete hangijzers en de inhoudelijke ideologische supplexen die er uitgevoerd worden zijn niet te negeren. Dankzij de evenredigheidsrichtlijn krijgen we als zorgverleners nu de kans om te reageren en ons bezwaar te uiten, zonder dat onze patiënten , noch de praktijkwerking hiervan de dupe hoeft te zijn. Met deze website heb ik de verschillende templates voor bezwaren proberen te bundelen, zodat deze vlot beschikbaar zijn en je deze naar eigen wens kan aanpassen dankzij het Word-format. Wie wil kan ook zijn RIZIV-nr achterlaten, zodat we kunnen opvolgen hoeveel inzendingen er zijn. Dit is niet zonder belang want meerdere politieke actoren hebben al duidelijk gemaakt dat indien er een groot aantal inzendingen zijn, hier toch iets met gedaan zal moeten worden. Het is eveneens duidelijk dat het kabinet geen zin had in deze bevraging, gezien ze dit pas hebben uitgeschreven op dwingende vraag van een juridisch advies en daarbij zelfs de minimale tijdsduur van 8 weken niet respecteren (mi. is het RIZIV lijdend voorwerp in deze). Uw bezwaar insturen kan dus zéér zeker een verschil maken. Spoor daarom ook uw collega's, uw medische raad, uw beroepsgroep,... aan om een bezwaar in te sturen en breng deze site onder aandacht bij uw collega's! kaderwet.be @SGeysenbergh @josvanhoof1957 @BLANCKAERTJoha1 @DeClercqLuc @frederik_kao @BOVYN @theharleydoc @GevaertThomas @daviddesmetmed @DanBacquelaine @ancapoen @catherinefonck @FriedaGijbels @louis_ide @KDepoorterMP @ASGB_KARTEL @bvastweets @DominiekSneppe @IrinaDeKnop

Artsen krijgen eindelijk houvast om te reageren op de kaderwet - despecialist.eu/nl/nieuws/bero… @NDeMeurechy @GevaertThomas @DeClercqLuc @BLANCKAERTJoha1 @dr_wardsam @bvastweets @ASGB_KARTEL

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7 Editorial: Early Detection of Prostate Cancer — Time to Fish or Cut Bait nej.md/47tKwfA

🚨23 years of PSA screening in @NEJM 🚨 👉ERSPC RCT of >162k patients 📅Median 23 year f/u PSA screening lead to... 📉 #prostatecancer mortality by 13% ✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa 📉Risk of advanced PCa by 34% ⭐️Benefit continues to rise over time as harm-benefit ratio improves 🔗shorturl.at/ajgNN @PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

📊 Göteborg-1 Trial – 25-Year Follow-up Extended follow-up from the Göteborg-1 screening trial confirms that active surveillance remains a safe and effective long-term strategy for well-selected men with low- and intermediate-risk prostate cancer. 🔹AS shows 94% PC-specific survival at 25 years (95% CI 91–98%); subgroup CSS at 24 years: 99%/92%/85% (very-low/low/intermediate). Continuous monitoring remains essential. 🔹 Conducted in the pre-MRI era 🔹 Modern imaging and biomarkers may further refine patient selection 📖 European Urology 2025;88:373–380 👉 buff.ly/PFmxP4j

Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy jamanetwork.com/journals/jamao… In this phase 2 randomized clinical trial evaluating PSMA-guided intensification of salvage radiotherapy (PSMAiSRT) after radical prostatectomy, 128 patients with biochemical recurrence were randomized to receive either standard-of-care salvage radiotherapy (SRT) or PSMA-PET/CT-guided, lesion-targeted SRT. Over a median follow-up of 37 months, PSMAiSRT significantly improved failure-free survival (HR 0.50, P = .04) and eugonadal failure-free survival (HR 0.45, P = .03), particularly among patients with PSA levels ≥0.3 ng/mL (HR 0.17, P = .01), without increasing toxicity or compromising quality of life. These findings suggest that PSMA-PET–guided SRT enables isotoxic intensification that enhances cancer control compared with standard imaging–based approaches, warranting confirmation in an ongoing phase 3 trial. #ProstateCancer @ColinBelliveau_ @taussky @mbarkati @AcadianRO @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

📊 #ProstateCancer in 2025: Key takeaways from @CACancerJournal 🚨 Incidence is rising again — +3%/yr since 2014, mostly advanced cases ⚠️ Mortality decline has stalled — only –0.6%/yr, w/ 35,770 deaths projected in 2025 📈 Distant-stage disease up in all ages: ~3%/yr (<55) & ~6%/yr (≥55) 💔 5-yr Survival: ~100% (localized/regional) vs ~38% (distant) 👉 Stark disparities — Black men: 67% higher incidence, 2x mortality; AIAN men: higher mortality despite lower incidence ➡️ Progress slowing, advanced cases rising, inequities persistent. 🚨Time for better screening + equity-focused solutions 🔗shorturl.at/5ClK2 @PCFnews @urotoday @UrologyTimes #prostatecancerawarenessmonth

The WHO/ISUP grading system is now preferred over Fuhrman grading for RCC. It offers better prognostic accuracy and less observer variability. Use it alongside RCC subtype classification. #EAUguidelines #KidneyCancer #UroOnc uroweb.org/guidelines/ren…

📢 New in European Urology: A meta-analysis of 43 studies (8,119 pts) confirms the diagnostic value of PSMA PET in prostate cancer BCR by Mazzone et al. 🔹 Positivity: 60% post-RP, 92% post-RT 🔹 48% positivity even at PSA 0.2–0.5 ng/ml 🔹 Site matters: pelvic nodes > bone > viscera 🔗 buff.ly/HwHJm92 #PSMAPET #BCR #ProstateCancer #UroOncology #EurUrol

🔬 New in @EUEuropeanUrol: The PUrE RCT 1 compares FURS vs. ESWL for lower pole kidney stones ≤10 mm. 🧑⚕️💰 A landmark trial on both clinical and cost effectiveness. #UroTwitter #Urolithiasis 1/ 📈 Findings from 461 randomized patients (48 UK centers): ✔️ Stone-free: FURS 72% vs ESWL 36% ✔️ Retreatments: FURS 9% vs ESWL 27% ✔️ Health status (EQ-5D): similar ✔️ Cost: ESWL significantly cheaper 2/ 💡 FURS delivers better clearance, but at higher cost (£65K/QALY). ➡️ ESWL provides equivalent QoL at lower cost — making it more cost-effective in the UK NHS system. 3/ 📢 Practice-changing implications for #Endourology ✅ Personalized decision-making ✅ Counselling on retreatment risk vs. resource burden ✅ Reinforces 2019 NICE guidance favoring ESWL for stones <10 mm 4/ Full open-access paper: 📄buff.ly/ydhdG36 #FURS #ESWL #KidneyStones #RCT #Urology #EU25 #CostEffectiveness #SharedDecisionMaking #BAUS